GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX ...

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Investing.com - 市值17.8亿美元的GoodRx Holdings Inc. (NASDAQ: GDRX )在周二美祖证券的研究报告中维持"中性"评级和5.00美元的目标价。该股近期表现强劲，过去一周上涨超过46%。根据 InvestingPro 分析，该公司的整体财务健康状况被评为"优秀"。

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...

Investing.com - 美国银行证券 (BofA Securities)在GoodRx Holdings Inc. (NASDAQ: GDRX )最新产品公告后，维持其"表现不佳"评级和3.40美元的目标价。根据 InvestingPro 数据，该股目前交易价格为5.07美元，分析师目标价范围从3.40美元到7.00美元不等，表明尽管公司拥有93.68%的高毛利率，市场情绪仍然喜忧参半。

GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading U.S. digital healthcare platform that helps consumers compare prescription ...

Healthcare tech company GoodRx (NASDAQ:GDRX) in Q2 CY2025 as sales only rose 1.2% year on year to $203.1 million. Its ...

GoodRx (NASDAQ:GDRX) jumped 18% after revealing a partnership with Novo Nordisk (NYSE:NVO) to offer Ozempic and Wegovy to ...